I'm aware of what the definition is. Do you believe there is no further in vitro or in vivo testing of any compound in the pipeline going on at this time? If so, I think you're wrong and stand by my statement. I'd also be curious why you think all other preclinical development would be stopped at this time with the number of potential indications Brilacidin has.

I'd actually be very excited if that were the case as it would hint toward an acquisition. I would expect we are still chugging along in the lab though.